News Column

Miraculins Announces National Accreditation of Pharmacist Education Program on Cardiovascular Risk Assessment with Focus on Skin Cholesterol

Mar 15 2013 12:00AM

Marketwire

LogoTracker

WINNIPEG, MANITOBA -- (Marketwire) -- 03/15/13 -- Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, in conjunction with Pear Healthcare Solutions, today announces the accreditation of a national program for pharmacists with the course name Cardiovascular Risk Assessment: Focus on Non-Invasive Skin Cholesterol Screening.

All Canadian pharmacists are under obligation by their respective provincial authorities to engage in lifelong learning and competency enhancements that supports optimal, patient centered, outcome focused care through medication management and effective pharmacy practice. With the national accreditation of the cardiovascular (CV) risk assessment education program, Canadian pharmacists can now earn credits to meet this requirement by learning about the benefits of providing CV risk assessment onsite, and skin cholesterol's role within that environment as an emerging biomarker in coronary artery disease risk assessment and screening.

The three modules of the program available at www.healthelearning.ca include:

Module 1 -    Cardiovascular Risk Assessment Background        (0.50 CEU)Module 2 -    Non-invasive Skin Cholesterol Testing as an      (0.50 CEU)              Option for CV Risk AssessmentModule 3 -    Communication and Action Plans                   (0.50 CEU)


"The retail pharmacy segment is an important distribution channel for the PreVu® Non-Invasive Skin Cholesterol Point of Care (POC) Test," said Christopher J. Moreau, President and CEO of Miraculins Inc. "The newly accredited program for cardiovascular risk assessment is another important step forward in educating pharmacists about the science and biology of skin cholesterol and its role in coronary artery disease risk assessment. This will provide a very important educational foundation for pharmacists as we work in parallel towards offering the PreVu POC Test to all potentially at-risk Canadians through additional national, regional and independent pharmacy locations."

About the PreVu Non-Invasive Skin Cholesterol Test

The PreVu® Non-Invasive Skin Cholesterol Point of Care (POC) Test is a non-invasive, risk assessment technology designed to measure skin cholesterol - an emerging biomarker in helping to assess risk of coronary artery disease ("CAD"). The PreVu® POC Test is completely painless, non-invasive, involves no blood draw or needles, and requires no overnight fasting. The test is conducted on the palm of the hand in less than 5 minutes with results being immediately available, facilitating point of care consultation and a next steps discussion. Skin cholesterol is the cholesterol that has been deposited and diffused into tissue, as opposed to freely circulating in the bloodstream, and the skin contains approximately 11% of all the cholesterol found in the human body, by weight. Elevated skin cholesterol has been shown in clinical studies to be strongly associated with an increased risk of significant CAD as measured by treadmill stress testing and coronary angiography, as well as measured by testing for coronary calcium, carotid artery thickening, and carotid artery plaque. The PreVu POC Test does not diagnose the presence or absence of CAD, but helps to identify patients who may be at higher, hidden risk for CAD by measuring their levels of skin cholesterol. The PreVu POC Test is not a substitute or replacement for blood serum cholesterol testing. For more information visit www.prevu.com.

Continued | 1 | 2 | Next >>

Story Tools